430 related articles for article (PubMed ID: 35408895)
21. The Effect of Testosterone Replacement Therapy on Penile Hemodynamics in Hypogonadal Men With Erectile Dysfunction, Having Veno-Occlusive Dysfunction.
Efesoy O; Çayan S; Akbay E
Am J Mens Health; 2018 May; 12(3):634-638. PubMed ID: 29575969
[TBL] [Abstract][Full Text] [Related]
22. Update in testosterone therapy for men.
Corona G; Rastrelli G; Forti G; Maggi M
J Sex Med; 2011 Mar; 8(3):639-54; quiz 655. PubMed ID: 21711483
[TBL] [Abstract][Full Text] [Related]
23. Testosterone replacement therapy in males with erectile dysfunction.
Jacob BC
J Pharm Pract; 2011 Jun; 24(3):298-306. PubMed ID: 21676853
[TBL] [Abstract][Full Text] [Related]
24. Optimal diagnostic measures and thresholds for hypogonadism in men with HIV/AIDS: comparison between 2 transdermal testosterone replacement therapy gels.
Blick G
Postgrad Med; 2013 Mar; 125(2):30-9. PubMed ID: 23816769
[TBL] [Abstract][Full Text] [Related]
25. Testosterone replacement therapy and prostate cancer: a word of caution.
Brand TC; Canby-Hagino E; Thompson IM
Curr Urol Rep; 2007 May; 8(3):185-9. PubMed ID: 17459266
[TBL] [Abstract][Full Text] [Related]
26. Adult- and late-onset male hypogonadism: the clinical practice guidelines of the Italian Society of Andrology and Sexual Medicine (SIAMS) and the Italian Society of Endocrinology (SIE).
Isidori AM; Aversa A; Calogero A; Ferlin A; Francavilla S; Lanfranco F; Pivonello R; Rochira V; Corona G; Maggi M
J Endocrinol Invest; 2022 Dec; 45(12):2385-2403. PubMed ID: 36018454
[TBL] [Abstract][Full Text] [Related]
27. Chronic Testosterone Deprivation Sensitizes the Middle-Aged Rat Brain to Damaging Effects of Testosterone Replacement.
Smith C; Contreras-Garza J; Cunningham RL; Wong JM; Vann PH; Metzger D; Kasanga E; Oppong-Gyebi A; Sumien N; Schreihofer DA
Neuroendocrinology; 2020; 110(11-12):914-928. PubMed ID: 31671430
[TBL] [Abstract][Full Text] [Related]
28. Critical Update of the 2010 Endocrine Society Clinical Practice Guidelines for Male Hypogonadism: A Systematic Analysis.
Seftel AD; Kathrins M; Niederberger C
Mayo Clin Proc; 2015 Aug; 90(8):1104-15. PubMed ID: 26205546
[TBL] [Abstract][Full Text] [Related]
29. Testosterone replacement therapy among elderly males: the Testim Registry in the US (TRiUS).
Bhattacharya RK; Khera M; Blick G; Kushner H; Miner MM
Clin Interv Aging; 2012; 7():321-30. PubMed ID: 22956867
[TBL] [Abstract][Full Text] [Related]
30. Negative Impact of Testosterone Deficiency and 5α-Reductase Inhibitors Therapy on Metabolic and Sexual Function in Men.
Traish AM
Adv Exp Med Biol; 2017; 1043():473-526. PubMed ID: 29224108
[TBL] [Abstract][Full Text] [Related]
31. Testosterone replacement therapy and cardiovascular events.
Çatakoğlu AB; Kendirci M
Turk Kardiyol Dern Ars; 2017 Oct; 45(7):664-672. PubMed ID: 28990951
[TBL] [Abstract][Full Text] [Related]
32. Risks of testosterone replacement therapy in men.
Osterberg EC; Bernie AM; Ramasamy R
Indian J Urol; 2014 Jan; 30(1):2-7. PubMed ID: 24497673
[TBL] [Abstract][Full Text] [Related]
33. Testosterone therapy of men with type 2 diabetes mellitus - a randomized, double-blinded, placebo-controlled study.
Magnussen LV
Dan Med J; 2017 Jul; 64(7):. PubMed ID: 28673384
[TBL] [Abstract][Full Text] [Related]
34. Testosterone treatment in the aging male: myth or reality?
Nigro N; Christ-Crain M
Swiss Med Wkly; 2012; 142():w13539. PubMed ID: 22430839
[TBL] [Abstract][Full Text] [Related]
35. Testosterone and the aging male: to treat or not to treat?
Bain J
Maturitas; 2010 May; 66(1):16-22. PubMed ID: 20153946
[TBL] [Abstract][Full Text] [Related]
36. Cardiovascular and Cerebrovascular Safety of Testosterone Replacement Therapy Among Aging Men with Low Testosterone Levels: A Cohort Study.
Loo SY; Azoulay L; Nie R; Dell'Aniello S; Yu OHY; Renoux C
Am J Med; 2019 Sep; 132(9):1069-1077.e4. PubMed ID: 30953635
[TBL] [Abstract][Full Text] [Related]
37. Late-life onset hypogonadism: a review.
Bassil N; Morley JE
Clin Geriatr Med; 2010 May; 26(2):197-222. PubMed ID: 20497841
[TBL] [Abstract][Full Text] [Related]
38. Testosterone treatment is not associated with increased risk of prostate cancer or worsening of lower urinary tract symptoms: prostate health outcomes in the Registry of Hypogonadism in Men.
Debruyne FM; Behre HM; Roehrborn CG; Maggi M; Wu FC; Schröder FH; Jones TH; Porst H; Hackett G; Wheaton OA; Martin-Morales A; Meuleman E; Cunningham GR; Divan HA; Rosen RC;
BJU Int; 2017 Feb; 119(2):216-224. PubMed ID: 27409523
[TBL] [Abstract][Full Text] [Related]
39. Influence of androgen receptor CAG polymorphism on sexual function recovery after testosterone therapy in late-onset hypogonadism.
Tirabassi G; Corona G; Biagioli A; Buldreghini E; delli Muti N; Maggi M; Balercia G
J Sex Med; 2015 Feb; 12(2):381-8. PubMed ID: 25443437
[TBL] [Abstract][Full Text] [Related]
40. [Therapy of the "aging male"].
Diemer T; Hauck EW; Rohde V; Weidner W
Urologe A; 2005 Oct; 44(10):1173-8. PubMed ID: 16151757
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
